{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:52:52Z","timestamp":1792554772418,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arvinas Estrogen Receptor, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01018-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:03:46Z","timestamp":1782734626000},"page":"613-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-7757","authenticated-orcid":false,"given":"Derek Z.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, et al. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res. 2024;30:3549\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465.","journal-title":"Clin Cancer Res"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic\u2014a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20:265\u201378. https:\/\/doi.org\/10.1038\/s41571-023-00736-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","volume":"27","author":"DA Nalawansha","year":"2020","unstructured":"Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol. 2020;27:998\u20131014. https:\/\/doi.org\/10.1016\/j.chembiol.2020.07.020.","journal-title":"Cell Chem Biol"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","volume":"19","author":"JS Thrower","year":"2000","unstructured":"Thrower JS. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000;19:94\u2013102. https:\/\/doi.org\/10.1093\/emboj\/19.1.94.","journal-title":"EMBO J"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393:556\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2505725.","journal-title":"N Engl J Med"},{"key":"1018_CR7","unstructured":"VEPPANU (vepdegestrant): Prescribing information. Pfizer Inc. 2026.\u00a0Accessed May\u00a08, 2026."},{"key":"1018_CR8","unstructured":"Johnson TR, Tran L, Bauman JN, Winton JA, Matschke KT. Absorption, metabolism, excretion, and pharmacokinetics of [14C] vepdegestrant in healthy adult participants. ISSX 14th International Meeting, Chicago; 2025."},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1002\/bcp.70198","volume":"91","author":"DZ Yang","year":"2025","unstructured":"Yang DZ, Zhou L, Winton JA, Matschke KT, Kantaridis C, Doyle K, et al. Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2025;91:3501\u201310. https:\/\/doi.org\/10.1002\/bcp.70198.","journal-title":"Br J Clin Pharmacol"},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"08","DOI":"10.1158\/1557-3265.SABCS24-P4-08-13","volume":"31","author":"S Drescher","year":"2025","unstructured":"Drescher S, Tan W, Zhang Y, Smith JP. Abstract P4-08-13: evaluating CYP3A4-mediated drug interaction risks for vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with cyclin-dependent kinase (CDK)4\/6 inhibitors and everolimus. Clin Cancer Res. 2025;31:08\u201308. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-P4-08-13.","journal-title":"Clin Cancer Res"},{"key":"1018_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70482","author":"H Wang","year":"2026","unstructured":"Wang H, Winton JA, Matschke KT, Stouffs A, Lee KC, Zhang Y, et al. Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. Br J Clin Pharmacol. 2026. https:\/\/doi.org\/10.1002\/bcp.70482.","journal-title":"Br J Clin Pharmacol"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clinthera.2025.12.007","volume":"48","author":"L Tran","year":"2026","unstructured":"Tran L, Winton JA, Matschke KT, Stouffs A, Lee KC, Zhang Y, et al. The effect of itraconazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting chimera estrogen receptor degrader, in healthy adult participants. Clin Ther. 2026;48:179\u201385. https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.007.","journal-title":"Clin Ther"},{"key":"1018_CR13","unstructured":"ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Bioequivalence for immediate release solid oral dosage forms (M13A). ICH; 2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M13A_Step4_Final_Guideline_2024_0723.pdf. Accessed April 25, 2026."}],"updated-by":[{"DOI":"10.1007\/s13318-026-01030-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000}}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01018-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:10Z","timestamp":1788980170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01018-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01018-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13318-026-01030-0","URL":"https:\/\/doi.org\/10.1007\/s13318-026-01030-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.Z.Y., K.T.M., J.A.W., K.C.L., and W.T. are employees of Pfizer, Inc. Y.Z. is an employee of Arvinas Operations, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with ethical principles from the Declaration of Helsinki and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice. Approval was received from a local independent ethics committee, and all local regulatory requirements were followed.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent before enrollment in the study and prior to undergoing any study-specific procedures.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}